The global anatomic pathology market was valued at USD 30.16 billion in 2022 and is projected to experience a robust growth trajectory, with an anticipated compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. A key driver behind this growth is the increasing adoption of biomarkers in clinical settings, which allows pathologists to gain valuable insights into molecular-level mechanisms underlying various diseases. This deeper understanding not only enhances clinical decision-making but also significantly contributes to improved patient outcomes. Consequently, there is a rising dependence on pathology tests and procedures that utilize biomarkers to examine prevalent malignancies and tumorigenesis. This trend towards biomarker-driven pathology is expected to significantly propel market growth.
Moreover, the adoption of advanced pathology equipment, which includes digital microscopes, gross imaging systems, and staining systems, is anticipated to greatly enhance anatomic pathology practices. Digital imaging solutions, in particular, provide substantial advantages in specificity and accuracy when compared to traditional techniques. This shift towards digital solutions is gaining momentum in the anatomic pathology market, driven by an increased demand for services that can deliver enhanced diagnostic precision and reliability.
Gather more insights about the market drivers, restrains and growth of the Anatomic Pathology Market
Application Insights Segmentation
Within the market, the disease diagnosis segment emerged as the dominant force, capturing the largest revenue share of 59.1% in 2022. Anatomic pathology plays a crucial role in disease diagnosis, providing researchers with the tools necessary to investigate disease etiology and associated outcomes thoroughly. This growing reliance on anatomic pathology protocols for disease diagnosis reflects a broader trend, as there is a notable surge in their application across various clinical settings. The primary catalyst for the growth of the disease diagnosis segment is the escalating prevalence of chronic conditions, particularly cancer, alongside a rising proportion of elderly individuals within the global population. These factors collectively contribute to a heightened demand for accurate and comprehensive disease diagnoses, which are facilitated by advanced anatomic pathology practices.
For example, in March 2023, PathAI, an AI-powered pathology company, launched its AISight platform, designed to evaluate the percentage of PD-L1 positive tumors and immune cells specifically in lung cancer cases. This innovative tool represents a significant advancement in the field, as PathAI's network of laboratories will be able to leverage its extensive and continuously evolving algorithm products across both oncology and non-oncology applications. The anatomic pathology workflow employed in these contexts aids in the early detection of tumors during critical stages characterized by inflammatory and proliferative stromal cell activity, thereby minimizing the costs associated with tumor eradication and improving overall treatment outcomes. Additionally, the growing focus among manufacturers on the introduction of innovative and novel diagnostic techniques further accelerates growth within this segment.
The drug discovery and development segment, meanwhile, is expected to exhibit the fastest CAGR of 9.2% over the forecast period from 2023 to 2030. In this realm, tissue analysis conducted by pathologists provides a wealth of critical information for pharmaceutical manufacturers, particularly during the preclinical trial phases. Anatomic pathology is vital for toxicology assessments, which evaluate the adverse effects of potential candidate drugs on living systems. For instance, in December 2022, Krishgen Biosystems launched its ELISA range, specifically designed for analyzing bispecific antibody drugs in plasma and serum samples. This development highlights the integral role that anatomic pathology plays in supporting drug discovery and development, as it continues to generate essential insights that inform and guide the pharmaceutical industry's research and development efforts.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
